RL
AZN icon

Ruffer LLP’s AstraZeneca AZN Stock Holding History

Ruffer LLP’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-28,965
Closed -$3.94M – 90
2022
Q4 		$3.94M Sell
28,965
-110,529
-79% -$13.9M 0.26% 47
2022
Q3 		$15.3M Sell
139,494
-15,355
-10% -$1.95M 0.96% 32
2022
Q2 		$20.5M Sell
154,849
-647,466
-81% -$85M 0.81% 32
2022
Q1 		$106M Sell
802,315
-127,801
-14% -$15.3M 2.49% 12
2021
Q4 		$109M Sell
930,116
-55,782
-6% -$6.56M 2.62% 11
2021
Q3 		$117M Buy
+985,898
New +$115M 3.7% 9

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ruffer LLP's AZN Position: Q1 2023 in Review

Ruffer LLP sold out of AstraZeneca (AZN) in Q1 2023, closing a stake of 28,965 shares — an estimated $3.94M sold.

Ruffer LLP first reported a position in AZN in Q3 2021 and held it in 6 quarters. The position peaked at $117M in Q3 2021. 1,054 funds tracked by Wall St. Rank hold AZN as of Q1 2023.

  • Ruffer LLP reported no remaining AstraZeneca position as of Q1 2023 after selling out during the quarter.
  • Ruffer LLP sold 28,965 AstraZeneca shares in Q1 2023, an estimated $3.94M.
  • Ruffer LLP first reported a position in AstraZeneca in Q3 2021 and held it in 6 quarters.
  • Ruffer LLP's AstraZeneca position peaked at $117M in Q3 2021.
  • 1,054 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2023.

Based on Ruffer LLP's 13F filing for Q1 2023, filed 11 May 2023.